| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
93,261,000 |
| Market
Cap: |
12.30(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1319 - $0.1319 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile First Wave BioPharma engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Co. is focused on developing its drug product candidate, MS1819, a yeast derived recombinant lipase for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. Co.'s b-lactamase program focuses on products with an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea by resistant bacterial strains induced by parenteral administration of several antibiotic classes. Co.'s compounds in pre-clinical development include: AZX1101 and AZX1103.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
3,256 |
3,520 |
19,349 |
24,671 |
| Total Sell Value |
$15,968 |
$17,077 |
$28,387 |
$41,693 |
| Total People Sold |
2 |
2 |
3 |
3 |
| Total Sell Transactions |
4 |
6 |
12 |
14 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Romano Sarah |
Chief Financial Officer |
• – – |
2024-04-01 |
4 |
S |
$4.23 |
$317 |
D/D |
(75) |
19,111 |
|
- |
|
| Sapirstein James |
Chairman and CEO |
• • – |
2024-04-01 |
4 |
S |
$4.23 |
$736 |
D/D |
(174) |
37,105 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2024-03-15 |
4 |
S |
$4.96 |
$5,555 |
D/D |
(1,120) |
19,186 |
|
- |
|
| Sapirstein James |
Chairman and CEO |
• • – |
2024-03-15 |
4 |
S |
$4.96 |
$9,360 |
D/D |
(1,887) |
37,279 |
|
- |
|
| Khosla Chaitan Phd |
Director |
– • – |
2024-03-13 |
4 |
A |
$0.00 |
$0 |
I/I |
440 |
440 |
|
- |
|
| Syage Jack |
President & COO |
• • – |
2024-03-13 |
4 |
A |
$0.00 |
$0 |
I/I |
15,400 |
15,400 |
|
- |
|
| Sapirstein James |
Chairman, President and CEO |
• • – |
2024-01-12 |
4 |
S |
$4.20 |
$697 |
D/D |
(166) |
39,166 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2024-01-12 |
4 |
S |
$4.20 |
$412 |
D/D |
(98) |
20,306 |
|
- |
|
| Casamento Charles J |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
19,633 |
19,937 |
|
- |
|
| Riddell Alastair |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
19,633 |
20,240 |
|
- |
|
| Coelho Mary Theresa |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
19,633 |
20,237 |
|
- |
|
| Borkowski Edward |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
19,633 |
20,248 |
|
- |
|
| Sapirstein James |
Chairman, President and CEO |
• • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
39,332 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
20,404 |
|
- |
|
| Sapirstein James |
Chairman, President and CEO |
• • – |
2023-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
17,660 |
19,332 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2023-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
12,614 |
13,404 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2023-10-04 |
4 |
S |
$0.29 |
$486 |
D/D |
(1,676) |
15,800 |
|
- |
|
| Sapirstein James |
President and CEO |
• • – |
2023-10-04 |
4 |
S |
$0.29 |
$802 |
D/D |
(2,764) |
33,397 |
|
- |
|
| Casamento Charles J |
Director |
– • – |
2023-09-15 |
4 |
S |
$0.43 |
$4 |
D/D |
(10) |
6,098 |
|
- |
|
| Casamento Charles J |
Director |
– • – |
2023-08-31 |
4 |
S |
$0.30 |
$1,816 |
D/D |
(6,053) |
6,108 |
|
- |
|
| Sapirstein James |
President and CEO |
• • – |
2023-07-03 |
4 |
S |
$1.54 |
$5,157 |
D/D |
(3,349) |
36,161 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2023-07-03 |
4 |
S |
$1.54 |
$3,045 |
D/D |
(1,977) |
17,476 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2023-04-03 |
4 |
S |
$2.50 |
$4,938 |
D/D |
(1,975) |
19,453 |
|
- |
|
| Sapirstein James |
President and CEO |
• • – |
2023-04-03 |
4 |
S |
$2.50 |
$8,368 |
D/D |
(3,347) |
39,510 |
|
- |
|
| Riddell Alastair |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
84,745 |
85,185 |
|
- |
|
104 Records found
|
|
Page 1 of 5 |
|
|
